Basque enterprise blog Receive daily information of interest to your company

28 May, 2020
The Basque Government participates in the Research and production project for the vaccine against COVID 19, together with Harvard and the company VIRALGEN

The Basque Government  is engaged in the international project to make this production possible in the Basque Country

Tapia highlights that, once Harvard advances with the vaccine, the Basque Country is ready to take on this opportunity that represents  a unique health, social and business advance

Viralgen Vector Core is a partnership uniquely positioned in the CDMO industry to bring forward a robust suspension platform for AAV production in a facility custom-designed to bring therapies to market as quickly as possible. Viralgen is able to support every aspect of your AAV program from start to finish, including large-scale manufacturing, fill-finish, and quality control in a GMP-certified environment in San Sebastian, Basque Country.

Harvard has chosen Viralgen Vector Core as it becomes the convergence point from experienced specialized organizations in biotechnology and life sciences, united with the aim of creating a CDMO in the cutting-edge sector of gene therapy and innovative medicines. Devoted to the Development and Manufacturing of viral vectors, in order to contribute to the progress in health and welfare of people.

NP_Viralgen_Covid_v16
AAVCOVID_partners_announcement_DRAFT_v2_VVC
Bio Health 3 February, 2020
VIVEbiotech SL new member of the Board of Directors of the Spanish Bioindustry Association (AseBio)

AseBio brings together more than 730 companies that employ almost 100,000 people and invest more...Leer más

Bio Health 2 October, 2019
VIVEbiotech makes a capital increase of 3.5 million euros to complete its expansion plan

  VIVEbiotech has carried out a capital increase of 3.5 million euros to finance its...Leer más

Bio Health 17 June, 2019
VIVEbiotech receives an issue notification of the patent grant for the LENTISOMA technology from the United States Patent and Trademark Office

LENTISOMA is a new generation lentiviral vector whose most outstanding feature is related to the...Leer más

Bio Health 28 January, 2019
Columbus launches a €70 million fund for biomedicine

With the new investment fund, the managers plan to build two new plants in San...Leer más

Linkedin

Daily information segmented according to business
sectors and countries of interest to make the most competitive
decisions

Latest news about New Subsidies

For SMEs, for diversifying markets, internships abroad, international tenders, non-reimbursable subsidies to consolidate exports, subsidies for deployments or specific training in internationalisation.

You’re interested, right?